Satellos Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2019
Cost of Revenue	1.51	0.6	6.68	2.76	1.6	Upgrade
Gross Profit	-1.51	-0.6	-6.68	-2.76	-1.6	Upgrade
Selling, General & Admin	8.03	6.04	5.03	3.47	1.31	Upgrade
Research & Development	16.92	13.76	-	-	-0.03	Upgrade
Amortization of Goodwill & Intangibles	-	-	-	-	0.13	Upgrade
Operating Expenses	24.95	19.8	5.03	3.47	2.17	Upgrade
Operating Income	-26.46	-20.4	-11.71	-6.23	-3.77	Upgrade
Interest Expense	-	-	-0.13	-	-0.04	Upgrade
Interest & Investment Income	1.36	1	1.01	0.05	0.01	Upgrade
Currency Exchange Gain (Loss)	0.4	1.67	-0.88	-0.05	0	Upgrade
Other Non Operating Income (Expenses)	-	-0	0	0	-8.46	Upgrade
EBT Excluding Unusual Items	-24.7	-17.73	-11.71	-6.23	-12.25	Upgrade
Asset Writedown	-	-2.91	-	-2.13	-	Upgrade
Other Unusual Items	-	-	-0.32	-	-	Upgrade
Pretax Income	-24.7	-20.63	-12.03	-8.36	-12.25	Upgrade
Income Tax Expense	0.17	-	-	0	-	Upgrade
Net Income	-24.87	-20.63	-12.03	-8.37	-12.25	Upgrade
Net Income to Common	-24.87	-20.63	-12.03	-8.37	-12.25	Upgrade
Shares Outstanding (Basic)	15	10	7	3	2	Upgrade
Shares Outstanding (Diluted)	15	10	7	3	2	Upgrade
Shares Change (YoY)	52.60%	32.84%	142.17%	48.20%	35.60%	Upgrade
EPS (Basic)	-1.70	-2.16	-1.67	-2.81	-6.11	Upgrade
EPS (Diluted)	-1.70	-2.16	-1.67	-2.81	-6.11	Upgrade
Free Cash Flow	-23.6	-18.26	-8.79	-4.17	-3.98	Upgrade
Free Cash Flow Per Share	-1.62	-1.91	-1.22	-1.40	-1.99	Upgrade
EBITDA	-26.46	-20.38	-11.7	-5.98	-3.64	Upgrade
D&A For EBITDA	0	0.02	0.01	0.25	0.13	Upgrade
EBIT	-26.46	-20.4	-11.71	-6.23	-3.77	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.